Showing results (1601-1610 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|September 18, 2009
The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemiaDaniel Polsky, Daria Eremina, Gregory Hess, et al.Pharmacoeconomics|August 12, 2009
Economic evaluations in the EURONHEED: a comparative analysisFlorencia Hutter, Fernando AntoñanzasPharmacoeconomics|November 18, 2010
The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developmentsAndrea Manca, Mark J Sculpher, Ron GoereePharmacoeconomics|June 8, 2012
Lost productivity in four European countries among patients with rheumatic disorders: are absenteeism and presenteeism transferable?Saskia Knies, Math J J M Candel, Annelies Boonen, et al.Pharmacoeconomics|January 31, 2014
Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010Torbjørn Wisløff, Gunhild Hagen, Vida Hamidi, et al.Pharmacoeconomics|December 3, 2013
The estimation of utility weights in cost-utility analysis for mental disorders: a systematic reviewMichael Sonntag, Hans-Helmut König, Alexander KonnopkaPharmacoeconomics|September 6, 2014
A primer on marginal effects--Part I: Theory and formulaeEberechukwu Onukwugha, Jason Bergtold, Rahul JainPharmacoeconomics|January 18, 2015
An educational review of the statistical issues in analysing utility data for cost-utility analysisRachael Maree Hunter, Gianluca Baio, Thomas Butt, et al.Pharmacoeconomics|November 21, 2014
Resource modelling: the missing piece of the HTA jigsaw?Praveen Thokala, Simon Dixon, Beate JahnPharmacoeconomics|March 23, 2016
Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not AvailableCatherine Beauchemin, Marie-Ève Lapierre, Nathalie Letarte, et al.Pageof 336